THE PLACE OF LEFLUNOMIDE IN DISEASE-MODIFYING THERAPY OF RHEUMATOID ARTHRITIS: NEW ASPECTS

Keywords: Rheumatoid arthritis, basic therapy, lefl unomide, effi cacy, tolerability

Abstract

A new mechanism of lefl unomide (LEF) action was recently discovered, namely its ability to infl uence the intracellular mechanism of the infl ammatory process by inhibiting JAK kinases, which brings it closer to the new most eff ective group for treatment of rheumatoid arthritis (RA) – Janus kinase inhibitors. The article presents data from both our own and other authors’ studies on the eff ectiveness and safety of the drug in comparison with other synthetic and biological basic agents. The aim of our study was a comparative evaluation of LEF, methotrex-
ate (MTX), sulfasalazine (SS) and their combinations (CDT) in 402 patients with RA. Obtained results showed advantages of LEF and СDT over the use of SS (at any RA duration) and MTX (at late RA). Adverse events were the lowest in the SS group, and disease-modifying anti-rheumatic drug (DMARD) discontinuation due to complications was the lowest in the LEF group. Based on the results of multifactor regression analysis, we developed a scheme of individualized selection of the most eff ective DMARD depending on the initial characteristics of RA patients. The article also presents international study data. It analyses the comparative effi cacy of LEF (10-20 mg/d) and low doses of rituximab (500 mg twice daily) in patients refractory to MTX therapy; effi cacy of LEF in monotherapy (5-40 mg/d) and combination with other DMARD; LEF at a dose of 100 mg/week and MTX at a dose of 10 mg/week; LEF at a dose of 50 mg once a week and 10 mg daily. The eff ect of LEF on uric acid levels and bone mineral density of the lumbar spine in patients with RA was studied.

Downloads

Download data is not yet available.

References

Masayo Kojima, Mieko Hasegawa, Shintaro Hirata, Hiromu Ito, Yuko Kaneko, Mitsumasa Kishimoto et al. Patients' perspectives of rheumatoid arthritis treatment: a questionnaire survey for the 2020 update of the Japan College of rheumatology clinical practice guidelines. Mod Rheumatol.2021; 19:1-6. DOI: 10.1080/14397595.2021.1913276

https://doi.org/10.1080/14397595.2021.1913276

Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease- modifying antirheumatic drugs: 2019 update FREE. Ann Rheum Dis. 2020;79(6):685-699. DOI: 10.1136/annrheumdis-2019-216655.

https://doi.org/10.1136/annrheumdis-2019-216655

Moon SJ, Kim EK , Jhun JY, Lee HJ, Lee WS, Park SH, Cho ML, Min JK. The active metabolite of leflunomide, A77 1726, attenuates inflammatory arthritis in mice with spontaneous arthritis via induction of heme oxygenase-1. J Transl Med. 2017;15(1):31. DOI: 10.1186/s12967-017-1131-x.

https://doi.org/10.1186/s12967-017-1131-x

Manna SK, Aggarwal BB. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression. J Immunol. 1999;162(4):2095-2102.

Urushibara M, Takayanagi H, Koga T, Kim S, Isobe M, Morishita Y, Nakagawa T, Löeffler M, Kodama T, Kurosawa H, Taniguchi T. The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-kappa B ligand-stimulated induction of nuclear factor of activated T cells c1. Arthritis Rheum. 2004;50(3):794-804. DOI: 10.1002/art.20206.

https://doi.org/10.1002/art.20206

Wang J, Sun J, Hu J, Wang C, Prinz RA, Peng D, Liu X, Xu X. A77 1726, the active metabolite of the anti-rheumatoid arthritis drug leflunomide, inhibits influenza A virus replication in vitro and in vivo by inhibiting the activity of Janus kinases. FASEB J. 2020 Aug;34(8):10132-10145. DOI: 10.1096/ fj.201902793RR.

https://doi.org/10.1096/fj.201902793RR

Siemasko K, Chong AS, Jäck HM, Gong H, Williams JW. A FinneganInhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production. J Immunol. 1998;160(4):1581-1588.

Li EK, Tam Lai-Shan, Tomlinson B. Leflunomide in the treatment of rheumatoid arthritis. Clin Ther. 2004 Apr;26(4):447-459. DOI: 10.1016/s0149-2918(04)90048-3

https://doi.org/10.1016/S0149-2918(04)90048-3

Iaremenko OB, Mikitenko GM. Efficacy and tolerability of leflunomide and methotrexate treatment in patients with early and late rheumatoid arthritis. Collection of scientific works of NMAPE named after PL Shupyk.-Issue 17, book 2.- Kyiv, 2008.-P.481-486.

Wijesinghe H., Galappatthy P., de Silva R, Silva R, Saravanamuttu U, Udagama P, Hart M, Kelleher P, Senerath U, Fernandopulle R, Weerasekera LP, Wijayaratne LS. Leflunomide is equally efficacious and safe compared to low dose rituximab in refractory rheumatoid arthritis given in combination with methotrexate: results from a randomized double blind controlled clinical trial. BMC Musculoskelet Disord. 2017;18: 310. DOI:https://doi.org/10.1186/s12891-017-1673-3.

https://doi.org/10.1186/s12891-017-1673-3

Deng D., Zhou J., Li M, Li S, Tian L, Zou J, Wang T, Wu J, Zeng F, Yang J. Leflunomide monotherapy versus combination therapy with conventional synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis: a retrospective study. Sci Rep.2020;10(1):12339. DOI:https://doi.org/10.1038/ s41598-020-69309-z.

https://doi.org/10.1038/s41598-020-69309-z

Jaimes-Hernández Jorge, Claudia Irene Meléndez-Mercado, Angélica Mendoza-Fuentes, Pablo Aranda- Pereira, Gilberto Castañeda-Hernández. Efficacy of Leflunomide 100mg Weekly Compared to Low Dose Methotrexate in Patients With Active Rheumatoid Arthritis. Double Blind, Randomized Clinical Trial. International Journal of Rheumatic Diseases. 2012; 8(Issue 5): 243-249. DOI: 10.1016/j. reumae.2012.07.005

https://doi.org/10.1016/j.reumae.2012.07.005

Li-Min Ren, Ru Li, Li-Na Chen, Ping Zhu, Fei Gu, Ling-Yun Sun, Jin-Xia Zhao, Xiang-Yuan Liu, Jia-Long Guo, Li-Qi Bi, Yan-Jie Hao, Zhuo-Li Zhang, Yi-Fang Mei, Zhi-Yi Zhang, Hua-Xiang Liu, Xing-Fu Li, Yan Luo, Yong-Fei Fang, Zhan-Guo Li, Yin Su. Efficacy and safety of weekly leflunomide for the treatment of early rheumatoid arthritis: a randomized, multi-center study. International Journal of Rheumatic Diseases. 2016; 19: 651-657. DOI: 10.1111/1756-185x.12677

https://doi.org/10.1111/1756-185X.12677

Perez-Ruiz F, Nolla JM. Influence of leflunomide on renal handling of urate and phosphate in patients with rheumatoid arthritis. Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases. 2003; 9(4):215-218. DOI: 10.1097/01.rhu.0000081470.31167.8b

https://doi.org/10.1097/01.rhu.0000081470.31167.8b

Kwon Oh Chan, Ji Seon Oh, Seokchan Hong, Chang-Keun Lee Conventional synthetic disease-modifying antirheumatic drugs and bone mineral density in rheumatoid arthritis patients with osteoporosis: possible beneficial effect of leflunomide. Clinical and Experimental Rheumatology.2019; 37(5):813-819.


Abstract views: 54
PDF Downloads: 37
Published
2022-06-27
How to Cite
1.
Iaremenko O, Mikitenko G. THE PLACE OF LEFLUNOMIDE IN DISEASE-MODIFYING THERAPY OF RHEUMATOID ARTHRITIS: NEW ASPECTS. Proc Shevchenko Sci Soc Med Sci [Internet]. 2022Jun.27 [cited 2022Oct.7];66(1). Available from: https://mspsss.org.ua/index.php/journal/article/view/661